ChartRow logo
Data provided bySource: Twelve Data
AXSM
$135.95-0.77%
as of close, Nov 17, 2026
☾ AH $135.95 -0.77%
Share this page

AXSM — Axsome Therapeutics Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in AXSM be worth today? →
AXSM returns: By year · By month · By week · Trailing

Price data

Price
$135.95
YTD price return
-25.56%
YTD total return
-25.56%
Market cap
7.2B
Enterprise value
7.1B
Shares outstanding
52.6M
52W low
$123.00
52W high
$260.19
From 52W high
-47.75%
From 52W low
+10.53%
52W range
9%$123–$260
Beta
0.72

Volume

Rel volume
0.49×
30D volume
1.1M
30D $ vol
155.8M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
−$2.1M
Insider net 1Y
−$100.9M

Form 4 transactions by trade date, as filed; latest on file 2026-09-03.

Fundamentals

Sales (ttm)
865.3M
Sales/share
$16.45
EPS (ttm)
-$3.05
FCF (ttm)
-82.6M
FCF/share
-$1.57
Book value/share
$2.00
Net margin
-18.18%
ROE
-149.19%
ROA
-19.02%
Debt / equity
1.12×
Current ratio
1.42

Growth (CAGR, ttm) · 10Y

Sales
+54.21%+57.02%n/an/a
Shares
+4.34%+3.59%+6.89%+10.63%

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+47.79%+51.58%n/an/a
Book value/share
+37.09%-29.39%+12.08%+3.14%
Price
-6.61%+31.42%+31.52%+33.87%
Total return
-6.61%+31.42%+31.52%+33.87%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-44.5×
Fwd P/E
41.9×
P/S (ttm)
8.3×
P/B (mrq)
67.8×
EV/Sales (ttm)
8.2×
FCF yield (ttm)
-1.16%
Buyback yield (realized, 1y)
-4.34%
Shareholder yield (realized, 1y)
-4.34%
Buyback yield (cash, ttm)
-0.36%
Shareholder yield (cash, ttm)
-0.36%

Vs own 10Y history

P/S
0th
P/B
67th

Bar = where today’s multiple sits in AXSM’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
-0.77%
5D
-3.56%
1M
-13.48%
3M
-37.14%
YTD
-25.56%
1Y
-6.60%
5Y
+293.49%
1D
-0.77%
5D
-3.56%
1M
-13.48%
3M
-37.14%
YTD
-25.56%
1Y
-6.60%
5Y
+293.49%

Fundamentals#

Revenue

YoY +51.9%
$865.3M TTM$259.7M Q3 '26
FY22FY23FY24FY25TTM
Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m
−$151M TTM−$11.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$3.05 TTM−$0.25 Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY n/m
−$82.6M TTM−$9.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$81.8M, capex −$839K

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow −$9.5M, capex −$197K

Shares (diluted)

5Y +33.7%5Y +33.7%YoY +4.8%
51.5M TTM52.4M Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m
−$157.3M TTM−$12.9M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full AXSM financials →

About Axsome Therapeutics#

Data provided bySource: Twelve Data

Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. Its marketed products include Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness related to narcolepsy or obstructive sleep apnea, and Symbravo for the acute treatment of migraine. The company also maintains a neuroscience pipeline spanning additional neurological and psychiatric conditions, reflecting its emphasis on disorders with limited treatment options. Axsome Therapeutics Inc. plays a specialized role in the healthcare market by combining commercial products with ongoing clinical development in psychiatry, sleep medicine, pain, and migraine care. Based in New York, the company is positioned as a focused CNS innovator serving patients, physicians, and healthcare systems with therapies designed to address unmet medical needs.

New York, NY·1,346 employees·Biotechnology·axsome.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding AXSM#

18 of the 193 ETFs ChartRow carries live hold AXSM. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF0.8%
VBKVanguard Small-Cap Growth ETF0.3%
IWPiShares Russell Mid-Cap Growth ETF0.3%
VBVanguard Small-Cap ETF0.1%
VXFVanguard Extended Market ETF0.1%
VHTVanguard Health Care ETF0.1%
IWRiShares Russell Midcap ETF0.1%
IWFiShares Russell 1000 Growth ETF0.0%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%